NOT FOR REPRINT
Page Printed from: benefitspro.com/author/profile/allison?page=31
Sign In To follow
The Senate committee chair wants to know why the drugs cost up to 15 times more in the United States than elsewhere.
The physician group approved a resolution to advocate for detailed explanations for coverage denials, which leads to "patient harm."
An NYU professor complained at a hearing last year that from small deals big antitrust problems grow.
Amazon, Google and JPMorgan Chase — which have made entries into the health care sector — all have speakers on the AHIP 2024 agenda.
The state attorney general may get the authority to reject some of them. Two employer groups like that.
The plaintiffs rely extensively on a New York Times article that ran in April.
S&P Global analysts continue to see drug costs as the top everyday concern.
A divided panel objected to the limits a trial court judge set on the evidence presented.
Ron Wyden and Bernie Sanders asked the company to brief their committee staffers.
Brokers and distributors predict chaos. CMS asks why they took so long to sue.